Skip to main content
Caplight Logo









Neobe Therapeutics

Neobe Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.neobetherapeutics.com/

Last Round

Seed

Feb 29, 2024

Total Funding Raised

$2.96M

Company Overview

Neobe Therapeutics is a biotechnology company developing a synthetic biology platform to engineer programmable bacteria that remodel the microenvironment of solid tumors to improve immunotherapy efficacy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

live biotherapeuticssynthetic biologyLBPtumor microenvironmentsynbiocancer immunotherapyengineered bacteriasolid tumor treatmentmicrobial therapeuticsdrug discovery platformbacterial cancer therapygenetic circuit designimmuno-oncologybiotech startupbacterial trojan horse

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neobe Therapeutics Comparables

Compare Neobe Therapeutics with similar companies based on industry and business-model similarity.

Neobe Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Prokarium
85%
Baccine Ltd.
81%
Ernest Pharmaceuticals
79%

Neobe Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 29, 2024
Pre SeedNov 22, 2022

Neobe Therapeutics Investors

Notable investors and investment history

Neobe Therapeutics investors
InvestorRounds
Deep Science VenturesSeed
Pioneer GroupSeed
Innovate UKSeed, Pre Seed
2048 VenturesSeed
Cancer Research HorizonsSeed
Discovery Park VenturesSeed, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Monthly visitors increased 51% MoM.

  • Sep 16, 2025

    Received the Pathfinder award at the Cambridge Business Weekly Awards.

Neobe Therapeutics Filings

Explore SEC and related filing metadata, where available.

Neobe Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neobe Therapeutics's valuation, stock price, and market status.

Is Neobe Therapeutics a public or private company?

Neobe Therapeutics is a private company.

What is the current stock price of Neobe Therapeutics?

Neobe Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Neobe Therapeutics worth (valuation)?

Valuation information for Neobe Therapeutics is not publicly available.

Can I buy Neobe Therapeutics stock?

Neobe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neobe Therapeutics's last funding round?

Neobe Therapeutics's most recent funding round was Seed on February 29, 2024.

Who are the main investors in Neobe Therapeutics?

Key investors in Neobe Therapeutics include Pioneer Group, Discovery Park Ventures.

Will Neobe Therapeutics IPO soon?

No public IPO plans have been announced for Neobe Therapeutics.

How can I track Neobe Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neobe Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range10
Year Founded2021
Last FundingFeb 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?